The Central Drugs Standard Control Organization (CDSCO) has directed all pharmaceutical companies operating in India to establish and maintain robust adverse event (AE) reporting systems and pharmacovigilance (PV) programs for their marketed drug products, as reported by The Economic Times and Medical Dialogues in early June 2026.
What CDSCO Directed
In a significant regulatory move, the drug regulator required pharmaceutical manufacturers to maintain systems capable of capturing, documenting, and reporting adverse drug reactions (ADRs) from healthcare professionals, patients, and other stakeholders. The directive applies to all drugs manufactured and marketed by Indian pharmaceutical companies, covering both domestic consumption and export-bound products.
The CDSCO specifically emphasized that safety data reporting must begin from the launch date of each drug product, not the approval date. This means companies must actively monitor and report adverse events starting when the product enters the market and reaches patients, rather than waiting until formal regulatory approval milestones. As reported by The Economic Times on May 10, 2026, the regulator’s position is that post-marketing surveillance must reflect real-world patient exposure from day one.
Why This Matters for Generic Medicine Buyers
For international buyers sourcing generic medicines from India, this pharmacovigilance mandate strengthens the regulatory safety net around Indian drug products. Here is why it matters:
- Improved post-market safety monitoring: Indian manufacturers are now formally required to track and report side effects from real-world use, supplementing the clinical trial data on which approval was based.
- Faster safety signal detection: A mandatory AE reporting system means potential safety issues can be identified and investigated more quickly than relying on voluntary reporting.
- Regulatory accountability: Companies that fail to maintain adequate PV systems face regulatory scrutiny — a meaningful enforcement tool that did not previously exist at this level of specificity.
- Aligment with international standards: The move brings Indian pharmacovigilance expectations closer to WHO-GMP and international regulatory norms, which is relevant for buyers in regulated markets.
Broader Drug Safety Context in India
This adverse event reporting directive builds on a wider push toward stronger drug safety infrastructure in India. Earlier in 2026, the CDSCO also:
- Directed pharma firms to maintain mandatory pharmacovigilance and ADR monitoring systems (June 2026, per Medical Dialogues and Pharmabiz)
- Mandated inclusion of specific adverse reaction warnings in package inserts for certain drugs — for example, requiring fixed drug eruption warnings in aceclofenac and ibuprofen prescribing information (July 2026, per Pharmabiz)
- Updated vancomycin labeling to include DRESS syndrome as a recognized adverse reaction (July 2026, per Medical Dialogues)
According to BioSpectrum India’s coverage in August 2026, drug safety has become “India’s next pharmaceutical imperative,” with the country’s growing export volumes making robust pharmacovigilance systems essential for maintaining regulatory credibility in international markets.
What This Means for Buyers
For procurement teams and healthcare providers sourcing Indian generic medicines, this CDSCO directive signals several practical developments:
- Safety documentation is becoming richer: Expect Indian manufacturers to provide more detailed post-marketing safety data as part of their regulatory dossiers and quality documentation.
- Due diligence now includes PV capability: When evaluating suppliers, buyers can ask about the supplier’s pharmacovigilance infrastructure — who monitors adverse events, how reports are submitted, and whether the company participates in India’s national ADR monitoring program coordinated by the Indian Pharmacopoeia Commission (IPC).
- Regulatory enforcement is real: The CDSCO has demonstrated willingness to direct specific labeling changes and mandate monitoring systems. This is not merely advisory guidance — it is a regulatory direction with compliance expectations.
India’s National Pharmacovigilance Program
India’s pharmacovigilance framework operates through the National Pharmacovigilance Programme, coordinated by the Indian Pharmacopoeia Commission (IPC) in collaboration with the CDSCO. The program collects ADR reports from healthcare professionals, hospitals, and pharmaceutical companies, and feeds safety signals into regulatory decision-making — including labeling changes, usage restrictions, and in rare cases, product withdrawals.
The 6th Drug Safety Symposium 2026, convened in May 2026 with over 100 pharmacovigilance leaders in attendance (as reported by Indian Pharma Post), highlighted the growing institutional focus on drug safety monitoring across India’s pharmaceutical sector.
Key Takeaways
- CDSCO has formally directed all Indian pharma companies to maintain adverse event reporting and pharmacovigilance systems for marketed drugs.
- Safety data reporting must start from the product launch date, not the approval date — reflecting real-world patient exposure.
- This strengthens post-market safety oversight and aligns Indian pharma more closely with international PV norms.
- Buyers sourcing Indian generics should factor pharmacovigilance capability into supplier due diligence.
Sources: The Economic Times (May 10, 2026), Medical Dialogues (June 5, 2026), Pharmabiz (June 5, 2026; July 28, 2026), BioSpectrum India (August 1, 2026), Indian Pharma Post (May 11, 2026).
For more information, contact IMSDA at contact@indiamedicine.org.